Taste responses in patients with Parkinson's disease

Sienkiewicz-Jarosz, H.; Scinska, A.; Kuran, W.; Ryglewicz, D.; Rogowski, A.; Wrobel, E.; Korkosz, A.; Kukwa, A.; Koslowski, W.; Bienkowski, P.
January 2005
Journal of Neurology, Neurosurgery & Psychiatry;Jan2005, Vol. 76 Issue 1, p40
Academic Journal
Objective: Predinical studies indicate that dopaminergic transmission in the basal ganglia may be involved in processing of both pleasant and unpleasant stimuli. Given this, the aim of the present study was to assess taste responses to sweet, bitter, sour, and sally substances in patients with Parkinson's disease (PD). Methods: Rated intensity and pleasantness of filter paper discs soaked in sucrose (10-60%), quinine (0.025-0.5%), citric acid (0.25-4.0%), or sodium chloride (1.25-20%) solutions was evaluated in 30 patients with PD and in 33 healthy controls. Paper discs soaked in deionised water served as control stimuli. In addition, reactivity to 100 ml samples of chocolate and vanilla milk was assessed in both groups. Taste detection thresholds were assessed by means of electrogustometry. Sociodemographic and neuropsychiatric data, including cigarette smoking, alcohol consumption, tea and coffee drinking, depressive symptoms, and cognitive functioning were collected. Results: In general, perceived intensity, pleasantness, and identification of the sucrose, quinine, citric acid, or sodium chloride samples did not differ between the PD patients and controls. Intensity ratings of the filter papers soaked in 0.025% quinine were significantly higher in the PD patients compared with the control group. No inter-group differences were found in taste responses to chocolate and vanilla milk. Electrogustometric thresholds were significantly (p =0.001) more sensitive in the PD patients. Conclusions: PD is not associated with any major alterations in responses to pleasant or unpleasant taste stimuli. Patients with PD may present enhanced taste acuity in terms of electrogustometric threshold.


Related Articles

  • Timing the initiation of treatment in Parkinson's disease. Grosset, Donald G.; Schapira, Anthony H. // Journal of Neurology, Neurosurgery & Psychiatry;Jun2008, Vol. 79 Issue 6, p615 

    The article presents views and insights of the author concerning the timing in the initiation of treatment in Parkinson's disease (PD). Clinical, imaging and pathological studies suggest that the cell loss begins 7 to 10 years before the onset of clinical features sufficient to allow the...

  • PROTEIN DEGRADATION: Parkin finds a partner and a victim. Brooksbank, Cath // Nature Reviews Molecular Cell Biology;Jan2001, Vol. 2 Issue 1, p4 

    Discusses research being done on proteins that cause Parkinson's disease. Reference to a study by Yi Zhang and colleagues, and published in the report "Proceedings of the National Academy of Sciences"; Rare cause that leads to autosomal recessive juvenile parkinsonism; Target for parkin.

  • Hemihypomimia, a rare persistent sign in Parkinson’s disease. Özekmekçi, Sibel; Benbir, Gülçin; Yavlal Özdogan, Figen; Ertan, Sibel; Kiziltan, Meral E. // Journal of Neurology;Mar2007, Vol. 254 Issue 3, p347 

    Typical hypomimia develops in almost all Parkinson’s disease (PD) patients. We observed the presence of hemihypomimia (HH) in some of our PD patients. To discern the presence of hemihypomimia, to compare clinical features of these patients with the patients without HH and then to evaluate...

  • In the news: Brain, heal thyself. Wood, Heather // Nature Reviews Neuroscience;Jun2002, Vol. 3 Issue 6, p420 

    Reports on a study conducted by researchers from the Frenchay Hospital in Bristol, Great Britain on alleviating some of the symptoms of Parkinson's disease. Administration of glial cell line-derived neurotrophic factor; Success of the study.

  • Parkinson Disease: A Review. Boe, Gerard P. // AMT Events;Jun2005, Vol. 22 Issue 2, p72 

    Presents information on Parkinson disease. Signs and symptoms; Progression of the disease; Findings of a study conducted by the National Parkinson Foundation on patients with Parkinsonism.

  • Parkinson's Disease Current Treatment. Wheaton, Jerry; Wright Jr., John M. // Officer Review Magazine;Nov2006, Vol. 46 Issue 4, p21 

    The article focuses on the current medications of Parkinson's disease, a degenerative disorder of the central nervous system characterized by tremor and impaired muscular coordination. Newer medications sustain the action of naturally produced dopamine by freezing the action of the enzyme that...

  • BEATING Parkinson's. Campbell, Annette; Gibson, Donna // Woman's Day (Australia Edition);4/18/2005, Vol. 57 Issue 16, p78 

    Provides information on Parkinson's disease. Cause of the disease; Manifestations of the disease; Available treatments; Relation of depression with Parkinsonism.

  • Verbal and visual memory in patients with early Parkinson's disease: Effect of levodopa. Singh, Sumit; Behari, Madhuri // Neurology India;Mar2006, Vol. 54 Issue 1, p33 

    Background: The effect of initiation of levodopa therapy on the memory functions in patients with Parkinson's disease remains poorly understood. Aims: To evaluate the effect of initiation of levodopa therapy on memory, in patients with early Parkinson's disease. Settings and Design: Prospective...

  • Should Parkinson's patients take CoQ10?  // Life Extension;2004 Collectors Edition, Vol. 10, p18 

    The article reports that Parkinson's disease is the second most common degenerative brain disorder. The percentage of the population afflicted by Parkinson's is on the rise. Researchers question why some people develop Parkinson's while others escape its clutches. One of the answers under...


Read the Article


Sign out of this library

Other Topics